What IP Lawyers Need to Know About California’s New Reverse Payment Law

What IP Lawyers Need to Know About California’s New Reverse Payment Law

Speaking Engagement CLE

Please join us on Thursday, January 30, 2020, for a webinar during which we will discuss California’s new reverse payment law—AB-824, Preserving Access to Affordable Drugs—and what it means for settlements of patent litigation involving generic pharmaceuticals and biosimilars across the nation. The webinar will feature Mark A. Ford, a partner in WilmerHale’s Antitrust and Competition Group, who focuses on issues at the antitrust-IP intersection.

During the webinar, we will:

  • break down the new law, which went into effect January 1, and highlight how the California law’s treatment of so-called reverse payment settlements differs from the treatment of those settlements under federal antitrust law in the wake of Fed. Trade Comm’n v. Actavis, 570 U.S. 136 (2013);
  • analyze the practical implications the California law has for litigation cost avoidance payments, which have been a common feature of Hatch-Waxman settlements, even after Actavis; and
  • provide an update on a pending constitutional challenge to California’s law, which is currently on appeal to the Ninth Circuit.

View the Webinar Recording*

*CLE credit is not available for those who watch webinar recordings.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.